Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CSTI-500
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ConSynance Receives Rare Pediatric Disease Designation for CSTI-500 in PW Syndrome
Details : CSTI-500 is a first-in-class, oral, triple monoamine reuptake inhibitor, small molecule drug candidate being evaluated for the treatment of prader-willi syndrome in children and adolescents.
Brand Name : CSTI-500
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 24, 2024
Lead Product(s) : CSTI-500
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CSTI-500
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CSTI-500 is a first-in-class, orally administered new chemical entity and an optimally balanced Triple Monoamine Reuptake inhibitor (TRI). It is being investigated for the treatment for prader-willi syndr...
Brand Name : CSTI-500
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2023
Lead Product(s) : CSTI-500
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?